Navigation Links
Weight Watchers Announces Third Quarter 2007 Results
Date:11/6/2007

s of 2006. As previously explained, the Company increased its debt level during the first quarter of 2007. As a result, interest expense in the first nine months of 2007 was $82.6 million, up from $35.9 million in the first nine months of 2006, while fully diluted shares of the Company decreased.

Commenting on the Company's results, David Kirchhoff, President and Chief Executive Officer, said, "We are pleased with the solid financial results in the third quarter of 2007, which were primarily the result of the continuing positive impact of our Monthly Pass commitment plan in North America and the strong performance of our Weight Watchers Online internet product. This year, we have put in place the building blocks which will allow us to benefit from more effective marketing and new program innovations in 2008."

The Company narrowed its full year 2007 earnings guidance range to between $2.43 and $2.48 per fully diluted share, which excludes $0.02 per share of non-recurring expense associated with the early extinguishment of debt in the first quarter of 2007.

The Company has scheduled a conference call today at 5:00 p.m. ET. During the conference call, David Kirchhoff, President and Chief Executive Officer, and Ann Sardini, Chief Financial Officer, will discuss third quarter results and answer questions from the investment community. Live audio of the conference call will be simultaneously webcast over the Internet on the Company's corporate website, http://www.weightwatchersinternational.com. A replay of the webcast will be available on this site for 30 days.

About Weight Watchers International, Inc.

Weight Watchers International, Inc. is the world's leading provider of weight management services, operating globally through a network of Company- owned and franchise operations. Weight Watchers holds over 50,000 weekly meetings where members receive group support and educ
'/>"/>

SOURCE Weight Watchers International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Early Weight Loss in Women Linked to Dementia
2. New research explores newborn in-hospital weight loss
3. Weight-Loss Surgeries Extend Lives
4. School-based overweight prevention program may cut risk of eating disorders among girls
5. Overweight toddlers and those not in day care at risk for iron deficiency
6. Weight Watchers Declares Quarterly Dividend
7. Eat Seafood, See Weight Loss: Recent Study Finds Another Reason to Eat Seafood for a Fit Lifestyle
8. Weight Gain May Spell Trouble for Heart Failure Patients
9. New Research From America On the Move Foundation Indicates American Weight Loss Efforts Stalling
10. Weight loss game looking for NEAT-o results
11. Aerobic, Weight Training Combo Best Against Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...cognise service excellence during National Custome... London (PRWeb UK) July 3, 2009 -- Companie...ged to celebrate the importance of excellent custo...rvice Week - 5-11 October., , ,Employers in all se...p and local authority see the week, which is organ...
(Date:7/3/2009)...th in middle age may triple the risk, study shows ... Middle-aged adults who live alone are twice as li...ter in life compared to those who are married or l...gher among those who are divorced or widowed, acco...chers. , The study included 2,000 men and women...
(Date:7/3/2009)...ia/ -- Sundia MediTech, a leading,integrated phar... in Shanghai,China announced today that Dr. Chen... Chemistry Services. , Prior to joining Sun...drug,discovery and development company in San Die...enior Director of Medicinal Chemistry of Neurocrin...
(Date:7/3/2009)...om launches new content to include information abo...o best deal with these health issues. , ...-- ReverseAges.com has recently launched a new ser...ommon health issues such as high blood pressure. H...rs, and the new content on ReverseAges.com address...
Breaking Medicine News(10 mins):Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...must in the medicine chest of a pregnant woman. It... lead to serious birth defects// in the baby. Foli...stroke and heart disease. Now, there appears to be... has shown. Folic acid may actually reduce low fr...
...n Ltd has received tentative approval from the US ... drug Sertraline Hydrochloride for// treatment of ...rtraline Hydrochloride tablets will be the AB-rate...zer's Zoloft tablets of 25mg, 50mg and 100mg dosag...
...mination in fish and birds in the northeastern Uni...five "hotspots" where concentrations// of the elem... health. The US and Canadian research team focuse...yellow perch and common loons, but it also took in...
...ormance measures for heart failure do not appear t... according to a study.// Heart failure continues ...d States: the overall prevalence of heart failure ...h 550,000 new cases being reported each year. Hear...
Other Medicine News:Health News:Mercury Contamination (Hotspots) Identified 2Health News:Most Hospital Performance Measures for Heart Failure Not Linked to Improved Patient Outcomes 2Health News:Most Hospital Performance Measures for Heart Failure Not Linked to Improved Patient Outcomes 3
(Date:7/2/2009)..., LEUVEN, Belgium and LUND, Sweden, July 3 /PR... Brussels: THR) and co-development partner,BioInv...have started,recruitment of a second cohort of pa...ollows completion of recruitment of the first coho... novel, long acting anticoagulant that,is being d...
(Date:7/1/2009)..., REYKJAVIK, Iceland, July 1 /PRNewswire-First...izophrenia ever undertaken has revealed several ne...f the human genome (SNPs) linked to,risk of the d...f scientists,led by a team from deCODE genetics (...n 50,000 patients and control participants from fo...
(Date:6/30/2009)..., MIDLOTHIAN, Va., June 30 In two ... Plus nebulizer and PRONEB compressors (Ultra and ...rol fumarate (Perforomist, DEY LP, Mylan Inc.) imp...that researchers chose PARI products as the exclus... maintenance treatments for COPD. Sutherland et a...
(Date:6/30/2009)..., SAN DIEGO, June 30 Calixa Therap...ase 2 clinical trial of CXA-101 in patients with c... new broad-spectrum, parenteral cephalosporin anti...ivity against Pseudomonas aeruginosa , including ...CXA-101 as a potential treatment for serious bacte...
Breaking Medicine Technology:ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 3ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 4ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 5deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 2Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections 2Transdel Pharmaceuticals to Present at Rodman 26 Renshaw 10th Annual Global Healthcare Conference 8883 1Transdel Pharmaceuticals to Present at Rodman 26 Renshaw 10th Annual Global Healthcare Conference 8883 2Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution TrialMaster 28TM 29 for Clinical Trials Management 3394 1Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution TrialMaster 28TM 29 for Clinical Trials Management 3394 2Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution TrialMaster 28TM 29 for Clinical Trials Management 3394 3Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts 8881 1Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts 8881 2Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts 8881 3VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 28713 1VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 28713 2VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 28713 3VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 28713 4VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 28713 5VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 28713 6
...eriority in Primary Endpoint of,In-Segment Late Lo... Target Vessel Failure and Superiority in Major Ad... Trial -, ABBOTT PARK, Ill., March 24, 2007 /PRNew...tt,s SPIRIT III U.S. pivotal clinical,trial at the... New,Orleans demonstrated the following key result...
...7 /PRNewswire/ -- A large patient,registry of "rea...Coronary Stent reported favorable safety and effic...linical investigators at the of,Cardiology,s 56th ...egistry is a prospective, single-arm study designe...y intervention (PCI,or balloon angioplasty) with t...
Other Medicine Technology:Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 2Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 3Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 4Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 5Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 2Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 3Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 4
The SOLX DeepLight Glaucoma Treatment System will provide less invasive, yet highly effective glaucoma treatments through the use of our DeepLight Gold Micro-Shunt (GMS) and DeepLight 790 Titanium Sa
The Verity ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to mee
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices.
The Identity ADx pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with the most advanced pacemaker technology available, including the revolutionary A
Medicine Products: